프론트바이오 - 로고

Press Releases

  • Notice
  • Press Releases
게시물 상세
FRONTBIO Inc. Launches Preclinical Trials for its New Anticancer Drug
작성일 : 2020-07-20   조회수 : 267

FRONTBIO Inc. Launches Preclinical Trials for its New Anticancer Drug

 

 

FRONTBIO, a bio company that develops new pharmaceuticals, announced on the 20th that it has developed 

a new anti-cancer drug that only kills cancer cells and will begin preclinical trials. 


FRONTBIO confirmed the anticancer drug candidate ‘FB320A3,’ signed a contract with the preclinical CRO (Contract Research Organization), and began 

the preclinical trials. The phase 1 clinical trial will begin in 2022."In the human pancreatic and colon cancer models transplanted into nude mice, 

most of the cancer cells disappeared after four weeks of oral administration of the candidate substances," the company said. "This is an excellent anticancer 

drug without resultant toxicity in the liver, kidneys, the spleen, or in the blood cells. Most of the extant cancer treatments are based on chemotherapy using 

cisplatin or 5-Fu, a drug that hinders genetic cloning, killing not only the cancer cells but also the normal cells. 


These types of treatments are known for their serious side effects and toxicity. In this new anticancer pharmaceutical treatment, the combined drugs were 

confirmed for their safety independently, already being prescribed for other diseases. This anticancer drug can be administered orally, making it easy to treat 

cancer without required hospitalization. Also, the price of the drug is considerably lower than those of targeted or immunotherapy pharmaceuticals. 

This will relieve the minds of cancer patients in terms of their financial burdens.” 


Six patents related to this anticancer drug under development have been registered and applied, and intellectual property rights have already been secured. 

"This anti-cancer drug is a combination of three drugs," said Lee Jae-Yong, CEO of FRONTBIO. "The first drug separates cancer cells from normal cells and causes

 the cancer cells to produce cell death-causing substances. The second and third drugs further amplify the production of this substance, eventually leading to only 

the deaths of the cancer cells. This is a new anticancer treatment with a new mechanism," he explained. 

"We have high expectations as it is does not demonstrate any toxicity to normal cells," Lee Jae-Yong emphasized.


이전글
다음글